Belén Garijo, chairman of the executive board and chief executive of Merck KGaA (MRK: DE), was able to reflect on another quarter of strong profitable growth at the German company.
Group net sales amounted to 5 billion euros ($5.7 billion), an increase of nearly 12% on the same period in 2020, with the Healthcare division responsible for 1.79 billion euros of this, a rise of 4.1% on a year ago.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze